MiR-625-5p is a potential therapeutic target in sepsis by regulating CXCL16/CXCR6 axis and endothelial barrier
International Immunopharmacology · 2024
DOI: 10.1016/j.intimp.2024.112508 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2024. Verfasst von Xiao Huang und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Intensive Care Unit, Binzhou Medical University Hospital, Binzhou, Shandong, China. Hauptthemen laut MEDLINE: Chemokine CXCL16, Lipopolysaccharides, MicroRNAs, Receptors, CXCR6. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Themen: Sepsis
Abstract (Originalsprache)
BACKGROUND: MicroRNA plays an important role in the progression of sepsis. We found a significant increase of in miR-625-5p expression in the blood of patients with sepsis, and lipopolysaccharide (LPS)-stimulated EA.hy926 cells. To date, little is known about the specific biological function of miR-625-5p in sepsis. METHODS: Changes in miR-625-5p expression were verified through quantitative real-time polymerase chain reaction in 45 patients with sepsis or septic shock and 30 healthy subjects. In vitro, EA.hy926 cells were treated with LPS. Transendothelial electrical resistance assay and FITC-dextran were used in evaluating endothelial barrier function. RESULTS: Herein, patients with sepsis or septic shock had significantly higher miR-625-5p expression levels, chemokine (C-X-C motif) ligand 16 (CXCL16) levels, and glycocalyx components than the healthy controls, and miR-625-5p level was positively correlated with disease. Kaplan-Meier analysis demonstrated a strong association between miR-625-5p level and 28-day mortality. Furthermore, the miR-625-5p inhibitor significantly alleviated LPS-induced endothelial barrier injury in vitro. Then, miR-625-5p positively regulated CXCL16 and down-regulated miR-625-5p attenuated CXCL16 transcription and expression in EA.hy926 cells. CXCL16 knockout significantly alleviated vascular barrier dysfunction in the LPS-induced EA.hy926 cells. sCXCL16 treatment in EA.hy926 cells significantly increased endothelial hyperpermeability by disrupting endothelial glycocalyx, tight junction proteins, and adherens junction proteins through the modulation of C-X-C chemokine receptor type 6 (CXCR6). CONCLUSIONS: Increase in miR-625-5p level may be an effective biomarker for predicting 28-day mortality in patients with sepsis/septic shock. miR-625-5p is a critical pathogenic factor for endothelial barrier dysfunction in LPS-induced EA.hy926 cells because it activates the CXCL16/CXCR6 axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Intensive Care Unit, Binzhou Medical University Hospital, Binzhou, Shandong, China.
- Department of Intensive Care Unit, Binzhou Medical University Hospital, Binzhou, Shandong, China; Department of Pulmonary and Critical Care Medicine, Yantai Yuhuangding Hospital, Yantai, Shandong, China.
- Department of Respiratory Medicine, Ji'nan Zhangqiu District People's Hospital, No. 1920 Mingshuihuiquan Road, Ji'nan, 250200, Shandong, China.
- Department of Intensive Care Unit, Binzhou Medical University Hospital, Binzhou, Shandong, China. Electronic address: wtsjr@163.com.
- Department of Intensive Care Unit, Binzhou Medical University Hospital, Binzhou, Shandong, China. Electronic address: hxicuwxz@163.com.
Zitieren
APA
Huang, X., Fei, Y., Qiu, X., Qian, T., Shang, Q., Cui, J., Song, Y., Sheng, S., Xiao, W., Yu, Q., Wang, T., & Wang, X. (2024). MiR-625-5p is a potential therapeutic target in sepsis by regulating CXCL16/CXCR6 axis and endothelial barrier. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2024.112508
Vancouver
Huang X, Fei Y, Qiu X, Qian T, Shang Q, Cui J, et al. MiR-625-5p is a potential therapeutic target in sepsis by regulating CXCL16/CXCR6 axis and endothelial barrier. International Immunopharmacology. 2024. doi:10.1016/j.intimp.2024.112508
BibTeX
@article{Huang2024,
author = {Huang, Xiao and Fei, Yuxin and Qiu, Xiaoyu and Qian, Tiantian and Shang, Quanmei and Cui, Jinfeng and Song, Yutong and Sheng, Shurui and Xiao, Wenhan and Yu, Qilin and Wang, Tao and Wang, Xiaozhi},
title = {MiR-625-5p is a potential therapeutic target in sepsis by regulating CXCL16/CXCR6 axis and endothelial barrier},
journal = {International Immunopharmacology},
year = {2024},
doi = {10.1016/j.intimp.2024.112508}
}
EUVIMED